ArticleIrish journal of medical science2025
The role of transforming growth factor beta-1 (TGF-β1) in the development of fibrosis in keratoconus.
Article in Irish journal of medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Iron overload triggers pathological remodeling of corneal stroma through ferroptosis and senescence-associated secretory phenotype in keratoconus.Redox biology · 2026Article
- Integrated multi-omics analysis combined with clinical validation reveals that HLA-DRB5 and ODAPH are causal risk genes for keratoconus.Scientific reports · 2026Article
- Five novelZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
backgroundThe etiology of keratoconus, a disease characterized by deterioration in the extracellular matrix and thinning of the corneal stroma, has not yet been fully elucidated. Recent studies have drawn attention to the relationship between TGF-β1 (Transforming Growth Factor Beta-1) and keratoconus because of its essential role in extracellular matrix secretion.
aimsThis study aimed to assess serum TGF-β1 levels in keratoconus patients and demonstrate its potential for estimating the severity of the disease. MATERIALS AND
methodsThe study prospectively included 63 patients diagnosed with keratoconus, followed-up between October 2023 and May 2024, and 65 healthy individuals. Patients were divided into four groups according to the Amsler-Krumeich classification. Serum TGF-β1 levels were measured from venous blood samples taken from the patient and control groups using ELISA.
resultsIn the patient group, TGF-β1 levels were 357.13 pg/ml (165.43-793.91) and 233.71 pg/ml (117.95-583.72) in the control group. TGF-β1 levels in the patient group were significantly higher than in the control group (p = 0.001). When keratoconus was examined according to stage, it was determined that TGF-β1 levels increased as the severity of the disease increased (p < 0.05 for all groups). No statistical difference was found between the groups in terms of age and gender.
conclusionConsidering that TGF-β1 is effective in the formation of fibrosis, high TGF-β1 levels may play a role in the scar formation observed in the advanced stages of keratoconus patients.
Indexed as
Identifiers
40767992What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.